All News

New ELCC 2026 data show longer survival, better brain metastases control and more personalized treatment options for patients with lung cancer.

Author and multiple myeloma survivor Jonathan Gluck shares how an unexpected diagnosis reshaped his identity and approach to living with uncertainty.

The 49th Annual Miami Breast Cancer Conference recently hosted a cornerstone event for the advocacy community: the CURE Educated Patient® Breast Cancer Summit.

Dr. Susan MacDonald, a urologist who has been diagnosed with stage 4 breast cancer, launches a new vlog series for CURE, “Demystifying the Darkness.”

Eight patients with NSCLC treated with ateganosine plus Libtayo had over 2-year survival after prior therapies, based on phase 2 THIO-101 trial data.

Author and survivor Parul Somani shares how patients with breast cancer can find peace of mind when clinical certainty is missing.

Early detection and grade-based care help manage immunotherapy toxicities, with tailored approaches for skin, gastrointestinal and cardiac side effects.

New NCCN guidelines highlight personalized combo treatments and new options to help patients with advanced kidney cancer live longer, better lives.

A couple shares how caregiving, communication and perspective shaped their life after liver cancer.

Amanda shares advice on resilience, self-advocacy and finding strength while navigating cancer survivorship and chronic GVHD.

FDA fast tracked ZW191 for platinum-resistant ovarian cancer, aiming to speed development of a potential new option for patients with limited treatments.

Black patients with early-stage lung cancer were less likely to receive curative treatment than White patients, despite all having Medicare coverage, study finds.

Learn about Ductal Carcinoma in Situ (DCIS), its diagnosis, treatment options and side effects. Empower yourself with information to navigate this journey with confidence.

Coverage from NCCN 2026 highlights global care delivery, younger patient needs, survivorship strategies and safer immunotherapy management.

Dr. Brittany Dulmage discusses how management of immune-related side effects can help patients stay on immunotherapy without compromising its effectiveness.

Global efforts in prevention, early detection and collaboration are improving cancer care access, but disparities persist based on where patients live.

Drs. Nunnery and McCann discuss the evolving HER2-positive breast cancer treatment paradigm in the latest episode of “Breast Cancer Briefing.”

FDA approves a PD-L1 test to help identify patients with esophageal or gastroesophageal junction (GEJ) cancer who may benefit from Keytruda.

Dr. Christopher H. Lieu highlights the rising cancer rate in younger adults and the need for more personalized, comprehensive care strategies.

New NCCN guidelines highlight how structured exercise and molecular profiling significantly reduce recurrence rates.

Experts highlight rising cancer rates in younger adults and the need for tailored support, treatment and survivorship care across the continuum.

COA updates on PBM reform, patient advocacy, and community oncology events to keep patients and advocates informed and empowered.

Hernexeos led to high response rates and disease control in HER2-mutant NSCLC, including patients with brain metastases, with manageable safety.

I struggle sometimes, wondering, “Why me?” and “Why testicular cancer?” Was God telling me something? Maybe to slow down and let him take control. So, I try my best to let go.

Amanda discusses the hidden challenges of chronic GVHD and how advocacy and storytelling help her support others facing similar struggles.

Tagrisso combined with chemotherapy improved how long patients with EGFR- and TP53-mutant NSCLC lived without their cancer worsening compared with Tagrisso alone.

A study found microplastics in prostate tumors, with higher levels in cancer tissue, prompting further research into potential links and health effects.

So many friends I have met along the way wanted so badly to live and they weren't able to. They didn't lose and I didn't win. We all walked through something really hard and got different outcomes.